Virbantel

Verify with FDA CVM →

10 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Virbantel

Administration Routes

OralUnknown

Species Affected

Dog 9
Cat 1

Most Affected Breeds

Beagle 2
Dog (unknown) 1
Domestic Shorthair 1
Hound (unspecified) 1
Dogue de Bordeaux 1
Bulldog 1
Mountain Dog - Bernese 1
Crossbred Canine/dog 1
Mastiff (unspecified) 1

Most Reported Reactions

Lack of efficacy (endoparasite) - hookworm 4
Lack of efficacy (endoparasite) - roundworm NOS 3
Injection site pain 1
Injection site abscess 1
Ataxia 1
Head tilt - neurological disorder (see also Head tilt - ear disorder) 1
Low platelet count 1
Eosinopenia 1
Elevated serum alkaline phosphatase (SAP) 1
Fever 1
Proteinuria 1
Hyposthenuria 1

Outcome Breakdown

Ongoing
8 (80.0%)
Outcome Unknown
2 (20.0%)

Data Summary

Metric Value
Total adverse event reports 10
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 9
Distinct reactions reported 18
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Virbantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 10 adverse event reports referencing Virbantel, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Virbantel. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Virbantel reports are Dog (9 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Beagle (2), Dog (unknown) (1), Domestic Shorthair (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Virbantel are Lack of efficacy (endoparasite) - hookworm (4), Lack of efficacy (endoparasite) - roundworm NOS (3), Injection site pain (1), Injection site abscess (1). Of the 10 reports with a coded outcome, Ongoing is the leading category at 80.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Virbantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial